靶向穿刺联合区域穿刺与联合系统穿刺的比较:系统评价与Meta分析结果
该系统评价与Meta分析纳入21项研究,比较靶向穿刺(TBx)联合区域穿刺(RBx)与靶向穿刺联合系统穿刺(TBx+SBx)对临床有意义前列腺癌(csPCa,ISUP分级分组≥2)的检出率。结果显示两组csPCa总体检出率无统计学差异(46.1% vs 44.2%;OR 1.07,95%CI 0.99-1.16,p=0.07)。作者结论支持在早期检测路径中使用TBx+RBx模板,当靶向MRI可见病灶时可省略SBx。
要点
- TBx+RBx与TBx+SBx对csPCa总体检出率无统计学差异(46.1% vs 44.2%;OR 1.07,95%CI 0.99-1.16,p=0.07)。
- TBx+SBx与ISUP分级分组1前列腺癌检出率较高相关(OR 1.16,95%CI 1.04-1.30,p=0.008)。
- 作者结论支持在早期检测路径中使用TBx+RBx模板,靶向MRI可见病灶时可省略SBx。
核心结论
- 本研究支持在早期检测路径中使用TBx+RBx模板检测csPCa,当靶向MRI可见病灶时可省略SBx。
研究设计与样本
- 系统评价与Meta分析,检索PubMed、Embase和Web of Science数据库至2023年9月,遵循PRISMA指南,纳入21项研究,采用QUADAS-2标准评估偏倚风险。
主要发现
- TBx+SBx与TBx+RBx的csPCa总体检出率无统计学差异(46.1% vs 44.2%;OR 1.07,95%CI 0.99-1.16,p=0.07)。
- ISUP分级分组≥3前列腺癌的检出率在TBx+SBx与TBx+RBx之间无统计学差异(OR 1.06,95%CI 0.92-1.22,p=0.43),各亚组分析结果相似。
- TBx+SBx与ISUP分级分组1前列腺癌检出率较高相关(OR 1.16,95%CI 1.04-1.30,p=0.008)。
关键数值与推荐
- csPCa定义为ISUP分级分组≥2。
- RBx定义为病灶周围或同侧穿刺。
- 纳入标准为报告SBx、TBx和TBx+RBx穿刺针数及其检出率数据的研究。
临床怎么用
- 作者结论支持在早期检测路径中使用TBx+RBx模板检测csPCa,当靶向MRI可见病灶时可省略SBx。
局限性
- 大多数纳入研究为回顾性研究。
- RBx定义和模板存在异质性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND OBJECTIVE: Intensification of targeted biopsy (TBx) around a magnetic resonance imaging (MRI)-visible lesion with regional biopsy (RBx) could obviate the need for systematic biopsy (SBx). We aimed to compare the detection yields of clinically significant prostate cancer (csPCa)-defined as International Society of Urological Pathology (ISUP) grade group ≥2-between TBx + RBx and the reference standard (TBx + SBx). METHODS: RBx was defined as perilesional or ipsilateral biopsy. A literature search was conducted up to September 2023 using PubMed, Embase, and Web of Science databases. The Preferred Reporting Items for Systematic Reviews and Meta-analyses (PRISMA) guidelines were followed. Included studies were eligible when presenting data from SBx, TBx, and TBx + RBx cores and their detection yields. The Quality Assessment of Diagnostic Accuracy Studies (QUADAS-2) criteria were used to assess the risk of bias of the included studies. KEY FINDINGS AND LIMITATIONS: Twenty-one studies were included for a meta-analysis. The overall detection yield of csPCa was not statistically different between TBx + SBX and TBx + RBx (46.1% vs 44.2%; odds ratio [OR] 1.07, 95% confidence interval [CI] 0.99-1.16, p = 0.07); similar findings were found also for ISUP grade group ≥3 prostate cancer (PCa; OR 1.06, 95% CI 0.92-1.22, p = 0.43) and in different subgroup analyses. TBx + SBx was associated with higher cancer detection of ISUP grade group 1 PCa (OR 1.16, 95% CI 1.04-1.30, p = 0.008). The main limitations include the retrospective nature of most of the selected studies, heterogeneity of RBx definition, and template. CONCLUSIONS AND CLINICAL IMPLICATIONS: Our study supports the use of the TBx + RBx template in the early detection pathway for the detection of csPCa. SBx can be omitted when targeting lesions visible on MRI. PATIENT SUMMARY: A prostate biopsy strategy consisting of taking biopsy in and around an magnetic resonance imaging-visible lesion reduces the risk of detecting indolent prostate cancers without affecting the detection of aggressive tumours.
引用
- Sanguedolce F, Lauwers CNG, Tedde A, et al. Regional Versus Systematic Biopsy in Addition to Targeted Biopsy: Results from a Systematic Review and Meta-analysis. Eur Urol Oncol. 2024. PMID: 39455339. doi:10.1016/j.euo.2024.10.006
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。